Local physician completes first U.S. case for end-stage critical limb ischemia

Metro Health – University of Michigan Health physician, Jihad A. Mustapha, MD, FACC, FSCAI, is the first in the U.S. to complete treatment on a patient utilizing the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System. The investigational device is used for the treatment of end-state critical limb ischemia (CLI) after all other efforts have been exhausted.

 

CLI can be a painful and limb-threatening for individuals who develop it. Common characterizations of CLI include pain at rest, ulcers, or gangrene in one or both legs stemming from arterial disease. Diabetics, smokers, and older individuals are among those with the highest rates of CLI.

 

“The only other disease with worse life expectancy than CLI is pancreatic cancer,” Mustapha, the study’s primary investigator, said. “Because of the mortality rate associated with amputations due to ischemia, a new approach to treat CLI is needed now more than ever. In the LimFlow study, we hope to help patients with no other options that are on their way to amputation.”

 

The procedure completed by Mustapha in July is the first case in the U.S. as part of an international feasibility study of the LimFlow system. The study is a multi-center, prospective, single-arm study conducted at three U.S. centers.

 

“The medical treatments being done at Metro Health – University of Michigan Health are pioneering,” said President and CEO Mike Faas. “I am so proud of the work of Dr. Mustapha, and all of those who comprise our Heart & Vascular team. They are so passionate about the work that they do—and are willing to push the level of care to new heights if it will safely and effectively increase the quality of life for patients.”

 

“I’m delighted that Metro Health – University of Michigan Health can lead the way in pioneering new treatments for patients,” Mustapha said. “This would not be happening here were it not for the vision of Mr. Faas, our president and CEO. Seven years ago we began work to fight the epidemic of CLI. In that time, our amputation prevention program has grown like no other in the country because the leadership at Metro believed in the pioneering work we were doing, and they recognized this work is improving the health and wellbeing of our community.”

Comments

comments